Individual differences |
Methods | Statistics | Clinical | Educational | Industrial | Professional items | World psychology |
Biological: Behavioural genetics · Evolutionary psychology · Neuroanatomy · Neurochemistry · Neuroendocrinology · Neuroscience · Psychoneuroimmunology · Physiological Psychology · Psychopharmacology (Index, Outline)
Probenecid chemical structure
|ATC code |
|Molecular weight||285.36 g/mol|
|Elimination half-life||2-6 hours (dose: 0.5-1 g)
4-12 hours (dose: >2 g)
|Routes of administration||oral|
Probenecid competitively inhibits the renal excretion of some drugs, thereby increasing their plasma concentration and prolonging their effects.
Uses[edit | edit source]
In one study, probenecid was shown to more than double blood concentrations of oseltamivir (trade name Tamiflu), an antiviral drug used to combat influenza. This is significant because nations are currently stockpiling oseltamivir in anticipation of an influenza pandemic, and there could be supply shortages.[How to reference and link to summary or text] During World War II, probenecid was used to extend limited supplies of penicillin, and is still currently used to increase antibiotic concentrations in serious infections.
Mechanism[edit | edit source]
Probenecid's exact mechanism is explained as follows. The kidney's organic anion transporter (OAT) reclaims uric acid from the urine and returns it to the plasma. Probenecid interferes with these systems. If probenecid (an organic acid) is administered to a patient, the OAT binds to probenecid instead of to uric acid, preventing the reabsorption of uric acid. As a result, more uric acid leaves the body in the urine, lowering the uric acid concentration in the plasma. This is an example of the way in which competition between substrates transported across cell membranes has been put to use in medicine.
See also[edit | edit source]
References[edit | edit source]
- MASON RM (June 1954). Studies on the effect of probenecid (benemid) in gout. Ann. Rheum. Dis. 13 (2): 120–30.
- Hill G, Cihlar T, Oo C, et al. (2002). The anti-influenza drug oseltamivir exhibits low potential to induce pharmacokinetic drug interactions via renal secretion-correlation of in vivo and in vitro studies. Drug Metab. Dispos. 30 (1): 13–9.
- Butler D (2005). Wartime tactic doubles power of scarce bird-flu drug. Nature 438 (7064): 6.
- Morra V, Davit P, Capra P, Vincenti M, Di Stilo A, Botrè F (December 2006). Fast gas chromatographic/mass spectrometric determination of diuretics and masking agents in human urine: Development and validation of a productive screening protocol for antidoping analysis. J Chromatogr A 1135 (2): 219–29.
- Hsyu PH, Gisclon LG, Hui AC, Giacomini KM (January 1988). Interactions of organic anions with the organic cation transporter in renal BBMV. Am. J. Physiol. 254 (1 Pt 2): F56–61.
|This page uses Creative Commons Licensed content from Wikipedia (view authors).|